SMMT Summit Therapeutics Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1599298 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY9.6%
TTM EPS YoY15.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-220.0%
ROA-174.5%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets18.5%
Debt / equity0.00x
Current ratio5.99x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.63x
Accruals ratio-64.4%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | $0 |
| R&D expense | $169.13M | $157.73M | $132.62M | $147.29M | $131.10M | $208.02M | $51.27M | $51.38M |
| SG&A expense | $45.48M | $62.76M | $62.59M | $77.63M | $103.11M | $360.42M | $15.59M | $14.23M |
| Operating income | — | — | — | — | — | — | — | -$65.61M |
| Interest expense | — | — | — | $0 | $0 | $0 | $0 | $9,000 |
| Net income | -$208.38M | -$215.70M | -$189.42M | -$219.17M | -$231.79M | -$565.71M | -$62.91M | -$61.20M |
| EBITDA | — | — | — | — | — | — | — | -$65.59M |
| EPS (basic) | -0.26 | -0.28 | -0.24 | — | -0.31 | -0.76 | -0.09 | — |
| EPS (diluted) | -0.26 | -0.28 | -0.24 | — | -0.31 | -0.76 | -0.09 | — |
| Weighted avg. shares (diluted) | 798.20M | 778.18M | 775.46M | — | 743.42M | 742.62M | 738.08M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $150.81M | $419.37M | $106.52M | $225.27M | $238.55M | $297.87M | $211.53M | $105.19M |
| Short-term investments | $478.98M | $271.31M | $492.22M | $488.18M | $0 | $0 | $149.79M | $307.49M |
| Current assets | $660.73M | $720.58M | $616.60M | $720.30M | $246.47M | $309.24M | $370.75M | $423.75M |
| PP&E, net | $2.53M | $1.78M | $1.66M | $1.06M | $810,000 | $690,000 | $652,000 | $254,000 |
| Goodwill | $1.98M | $1.97M | $1.97M | $2.00M | $2.00M | $2.04M | $1.92M | $1.86M |
| Intangibles | — | — | — | — | — | — | — | $0 |
| Total assets | $692.85M | $752.18M | $647.86M | $751.18M | $261.73M | $324.04M | $383.82M | $435.56M |
| Current liabilities | $110.23M | $103.57M | $83.27M | $72.99M | $64.93M | $60.33M | $34.88M | $41.73M |
| Total liabilities | $128.17M | $122.20M | $101.92M | $92.32M | $69.47M | $64.60M | $39.49M | $46.81M |
| Shareholders' equity | $564.68M | $629.98M | $545.93M | $658.86M | $192.26M | $259.44M | $344.33M | $388.75M |
| Shares outstanding | 799.73M | 793.12M | 776.02M | 775.37M | 744.44M | 742.81M | 741.61M | 737.63M |
| Cash flow statement | ||||||||
| Operating cash flow | -$159.81M | -$141.12M | -$122.29M | -$101.94M | -$93.08M | -$66.74M | -$61.17M | -$48.67M |
| Capital expenditure | $396,000 | $909,000 | $245,000 | $164,000 | $71,000 | $0 | $422,000 | $14,000 |
| Free cash flow | -$160.21M | -$142.03M | -$122.54M | -$102.10M | -$93.15M | -$66.74M | -$61.59M | -$48.69M |
| Investing cash flow | -$204.16M | $222.90M | -$238,000 | -$485.16M | -$71,000 | $150.81M | $160.11M | $83.48M |
| Financing cash flow | $95.43M | $231.08M | $3.80M | $573.82M | $33.81M | $2.22M | $7.68M | -$23.61M |
| Depreciation & amortization | $85,000 | $46,000 | $44,000 | $42,000 | $42,000 | $37,000 | $25,000 | $22,000 |
| Stock-based compensation | $47.69M | $68.71M | $72.79M | $111.78M | $130.76M | $478.78M | $11.10M | $11.02M |
Free plan shows the latest 8 periods; Pro shows all 40 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.